A New Risk Score Based on Lipid Indicators for Patients with Advanced Hepatocellular Carcinoma

被引:0
|
作者
Wei, Xing [1 ]
Guo, Ziwei [2 ]
Zhang, Tingting [3 ]
Liang, Jun [1 ]
机构
[1] Peking Univ Int Hosp, Dept Med Oncol, Beijing, Peoples R China
[2] Double Crane Runchuang Technol Beijing Co Ltd, Dept Med, Beijing, Peoples R China
[3] Capital Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Digest Hlth, Dept Gen Surg,Beijing Friendship Hosp, Beijing, Peoples R China
关键词
hepatocellular carcinoma; survival; prognosis; clinical response; risk score; DENSITY-LIPOPROTEIN-CHOLESTEROL; EMERGING ROLE; BIOMARKER; INDEX; RATIO;
D O I
10.2147/JHC.S505028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognosis is extremely troubling in advanced hepatocellular carcinoma (HCC). Prognostic scores have been developed. Yet, the positive predictive values might appear inadequate. This retrospective study aimed to develop a quick and efficient risk score to assess prognosis and clinical response. Methods: A total of 391 hCC patients were enrolled and were divided into training and validation groups between 2015 and 2024. Patients were separated into high-risk and low-risk groups using X-tile software. Using the COX proportional risk model analysis method, we then created a risk score and examined them using Kaplan-Meier, time-dependent receiver operating characteristics (ROC) curve, and nomogram analysis. Results: In predicting overall survival (OS), free fatty acid/high-density lipoprotein cholesterol (FFHL), tumor size, and BCLC stage were independent prognostic variables. A new risk score was developed just above and used as a prognostic factor (p < 0.001 in the training and validation groups) and had a high time-dependent ROC for progress-free survival (PFS) (area under the curve [AUC] 0.688-0.789 in the training group; AUC 0.592-0.741 in the validation group) and OS (AUC 0.812-0.918 in the training group; AUC 0.692-0.981 in the validation group). In comparison to the best overall response (BOR), the score offered a more accurate evaluation of durable clinical benefit (DCB) (p < 0.001 in the training and validation group; p = 0.061 vs 0.001 in the training and validation group). Conclusion: A new score based on lipid markers is a useful tool for evaluating prognosis and distinguishing patients with DCB.
引用
收藏
页码:107 / 121
页数:15
相关论文
共 50 条
  • [31] A classification based on tumor budding and immune score for patients with hepatocellular carcinoma
    Li Wei
    Zhang Delin
    Yuan Kefei
    Wu Hong
    Huang Jiwei
    Zhang Yange
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [32] The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma
    Akiyoshi Kinoshita
    Hiroshi Onoda
    Nami Imai
    Akira Iwaku
    Mutumi Oishi
    Ken Tanaka
    Nao Fushiya
    Kazuhiko Koike
    Hirokazu Nishino
    Masato Matsushima
    Chisato Saeki
    Hisao Tajiri
    BMC Cancer, 13
  • [33] The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma
    Kinoshita, Akiyoshi
    Onoda, Hiroshi
    Imai, Nami
    Iwaku, Akira
    Oishi, Mutumi
    Tanaka, Ken
    Fushiya, Nao
    Koike, Kazuhiko
    Nishino, Hirokazu
    Matsushima, Masato
    Saeki, Chisato
    Tajiri, Hisao
    BMC CANCER, 2013, 13
  • [34] A gene-based risk score model for predicting recurrence-free survival in patients with hepatocellular carcinoma
    Wang, Wenhua
    Wang, Lingchen
    Xie, Xinsheng
    Yan, Yehong
    Li, Yue
    Lu, Quqin
    BMC CANCER, 2021, 21 (01)
  • [35] A gene-based risk score model for predicting recurrence-free survival in patients with hepatocellular carcinoma
    Wenhua Wang
    Lingchen Wang
    Xinsheng Xie
    Yehong Yan
    Yue Li
    Quqin Lu
    BMC Cancer, 21
  • [36] Construction and validation of a nomogram for hepatocellular carcinoma patients treated by traditional Chinese medicine based on inflammation, nutrition, and blood lipid indicators
    Yu, Xiaopeng
    Yang, Renyi
    He, Zuomei
    Zeng, Puhua
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (11) : 8969 - 8979
  • [37] Mitochondrial Lipid Metabolism Genes as Diagnostic and Prognostic Indicators in Hepatocellular Carcinoma
    Li, Xuejing
    Tan, Ying
    Liu, Bihan
    Guo, Houtian
    Zhou, Yongjian
    Yuan, Jianhui
    Wang, Feng
    CURRENT GENOMICS, 2023, 24 (02) : 110 - 127
  • [38] A simple prognostic scoring system for patients treated with sorafenib for advanced hepatocellular Carcinoma: The SAP score
    Edeline, J.
    Blanc, J. F.
    King, J.
    Chatterjee, M.
    Mathurin, J.
    Le Sourd, S.
    Palmer, D.
    Meyer, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S443 - S444
  • [39] Construction and validation of a nomogram for hepatocellular carcinoma patients treated by traditional Chinese medicine based on inflammation, nutrition, and blood lipid indicators
    Xiaopeng Yu
    Renyi Yang
    Zuomei He
    Puhua Zeng
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 8969 - 8979
  • [40] CLINICAL OUTCOMES BY CHILD PUGH SCORE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA IN A COMMUNITY ONCOLOGY SETTING
    Aly, Abdalla
    Fulcher, Nicole
    Seal, Brian
    Trang Pham
    Paulson, Scott
    He, Aiwu Ruth
    HEPATOLOGY, 2020, 72 : 632A - 632A